Skip to main content

Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
obesity drugs
sodium-glucose co-transporter-2 (SGLT-2) inhibitor
Description

This report presents incidence and counts of 11 generic names contained in the National Drug Code (NDC) directory. Results include total and incident counts of dispensing of the selected drugs (generic names) among enrolled members in the Sentinel Distributed Database (SDD) from 2008 - 2017. Counts and incidence are calculated with 90-day, 180-day, and 270-day washout periods. Results are stratified by year.

The study period includes data from January 1, 2000 to August 31, 2018. We distributed this request to 17 Sentinel Data Partners on May 17, 2019.

 

Deliverables (2)
Sentinel Summary Table Report: Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis, Table 1 Sentinel Summary Table Report: Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis, Table 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - August 31, 2018
Analysis Type
Summary Table
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Anti-Obesity Medications (Benzophetamine, Bupropion/Naltrexone, Diethylpropion, Liraglutide, Lorcaserin, Orlistat, Phendimetrazine, Phentermine, Phentermine/Topiramate) & Duration of Use and Patient Characteristics